AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23787155
Drug: Low Hb
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Hb group (target Hb 9.0 ≤ target Hb ≤ 11.0 g/dL with recombinant human erythropoietin)
Trial: 21636031
Drug: UFH plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFH plus glycoprotein IIb/IIIa inhibitor (control group)
Trial: 1544739
Drug: 450 mg
RxNorm normalized name: aspirin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg caffeine with exercise (running for 30 min at 75% of maximum heart rate)
Trial: 1544739
Drug: 450 mg
RxNorm normalized name: aspirin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg caffeine without exercise
Trial: 3916264
Drug: Self-initiated treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-initiated treatment
Trial: 27312538
Drug: Menopausal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Menopausal hormone therapy (MHT) cream containing oestradiol 50mcg and norethisterone acetate 140mcg
Trial: 19170463
Drug: Citalopram (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (40 mg, fixed‐flexible dose)
Trial: 16791541
Drug: Once-daily modified-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily modified-release MPH (EqXL) at doses of 20, 40, or 60 mg
Trial: 16791541
Drug: Twice-daily immediate-release
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily immediate-release methylphenidate (MPH-IR) at doses of 10, 20, or 30 mg
Trial: 15531675
Drug: Beta-carotene (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (15 mg/d)
Trial: 9314869
Drug: Two-drug regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-drug regimen (doxorubicin 25 mg/m2 on days 1-3 and cisplatin 100 mg/m2 on day 1 for six cycles over 18 weeks)
Trial: 9314869
Drug: Multi-drug regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-drug regimen (preoperatively vincristine, high-dose methotrexate, and doxorubicin; postoperatively bleomycin, cyclophosphamide, dactinomycin, vincristine, methotrexate, doxorubicin, and cisplatin over 44 weeks)
Trial: 1824
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg d-amphetamine with lithium carbonate
Trial: 1824
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg l-amphetamine with lithium carbonate
Trial: 28482692
Drug: Baseline heart
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline heart rate (per 5 bpm increase) without β-blockers
Trial: 25845224
Drug: Acupoint-injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint-injection of BCG polysaccharide nucleic acid
Trial: 25845224
Drug: Intramuscular-injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular-injection of BCG polysaccharide nucleic acid
Trial: 22459649
Drug: Volumetric Modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volumetric Modulated Arc Therapy (RapidArc)
Trial: 15526012
Drug: rHuEpo (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEpo (300 units per kg per dose, subcutaneous, for 10 days) plus oral iron
Trial: 10563709
Drug: Lamivudine 150
RxNorm normalized name: lamivudine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 150 mg twice a day
Trial: 10563709
Drug: Lamivudine 300
RxNorm normalized name: lamivudine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 300 mg twice a day
Trial: 10563709
Drug: Lamivudine 150
RxNorm normalized name: lamivudine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 150 mg and 300 mg regimens
Trial: 9494257
Drug: Amtolmetin guacyl
RxNorm normalized name: Amtolmetin guacil
DrugBank: Amtolmetin guacil (DB16088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amtolmetin guacyl (1200 mg/day for first 3 days, then 600 mg/day for remaining 27 days)
Trial: 9494257
Drug: Diclofenac (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (150 mg/day in three daily administrations on a full stomach)
Trial: 18713921
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine patch (5 mg)
Trial: 18713921
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine patch (5-15 mg)
Trial: 10472510
Drug: High-dose (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (25 mg) nicotine patch therapy
Trial: 10472510
Drug: Standard-dose (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose (15 mg) nicotine patch therapy
Trial: 8117635
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml 0.5% bupivacaine with epinephrine
Trial: 3767037
Drug: Ketamine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (1 mg X kg‐1)
Trial: 3767037
Drug: Droperidol (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (0.1 mg X kg‐1)
Trial: 26472043
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) with loading dose (400 mg Weeks 0/2/4)
Trial: 26472043
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) without loading dose
Trial: 26472043
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) with loading dose
Trial: 24798614
Drug: First-line antiretroviral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line antiretroviral therapy (efavirenz or nevirapine with zidovudine/lamivudine or tenofovir/lamivudine)
Trial: 24798614
Drug: First-line antiretroviral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line antiretroviral therapy (in Nigeria)
Trial: 23169985
Drug: Ticagrelor 180
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 180 mg loading followed by 90 mg bid
Trial: 23169985
Drug: Prasugrel 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 60 mg loading followed by 10 mg od
Trial: 10226872
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate (4 x 200 mg/day, p.o.)
Trial: 8709351
Drug: Neoadjuvant androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant androgen withdrawal with 300 mg cyproterone acetate daily for 12 weeks
Trial: 26001387
Drug: Citalopram (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (30 mg single dose)
Trial: 23901669
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of bevacizumab (Avastin)
Trial: 22789792
Drug: Aromatherapy (inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatherapy (inhalation group or aromatherapy hand technique) with essential oil blend of rose otto and lavandula angustifolia @ 2% dilution, 15 min sessions, twice a week for four weeks
Trial: 19165115
Drug: Naltrexone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone treatment for 2 weeks
Trial: 17565326
Drug: Thymoglobulin induction
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoglobulin induction with tacrolimus, mycophenolate, and steroids
Trial: 11473908
Drug: Webster‐Stratton basic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Webster‐Stratton basic videotape programme administered to parents of six to eight children over 13‐16 weeks
Trial: 9870319
Drug: Zidovudine (ZDV)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV) therapy duration
Trial: 3132574
Drug: met‐hGH in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: met‐hGH in intravenous feeding
Trial: 31599561
Drug: Postoperative hypocalcemia
RxNorm normalized name: Drugs for treatment of hypercalcemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative hypocalcemia (<8.5 mg/dL)
Trial: 31599561
Drug: Severe hypocalcemia
RxNorm normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe hypocalcemia (<7.5 mg/dL)
Trial: 28665377
Drug: Pharmacopuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacopuncture treatment with anti-homotoxic agents (placental compositum, co-enzyme compositum, ubichinon compositum)
Trial: 28665377
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment including histamine H2-receptor antagonists, proton pump inhibitors, stimulators of gastrointestinal motility, alginates, and other drugs
Trial: 21348539
Drug: Vicriviroc with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicriviroc with ritonavir and protease inhibitors (fixed-sequence studies)
Trial: 21348539
Drug: Vicriviroc with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicriviroc with other antiretroviral agents
Trial: 21348539
Drug: Vicriviroc and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicriviroc and combination treatment
Trial: 21348539
Drug: Vicriviroc co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicriviroc co-administered with antiretroviral agents
Trial: 18509176
Drug: Docetaxel therapy
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel therapy in ER-positive patients
Trial: 18509176
Drug: Docetaxel therapy
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel therapy in ER-negative patients
Trial: 10737286
Drug: Controlled-release oxycodone
RxNorm normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Controlled-release oxycodone (mean dose approximately 40 mg/d after titration)
Trial: 8762741
Drug: District drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: District drug formulary
Trial: 18050628
Drug: 20 min
RxNorm normalized name: wheat germ oil 20 minim ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 min acupuncture treatment
Trial: 18050628
Drug: 40 min
RxNorm normalized name: ZINC OXIDE 17.5 g in 100 g TOPICAL STICK [Brush On Block Quick Stick SPF 40 Mineral Stick]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 min acupuncture treatment
Trial: 18050628
Drug: 60 min
RxNorm normalized name: TITANIUM DIOXIDE 6 g in 100 g / ZINC OXIDE 4.6 g in 100 g TOPICAL STICK [SPF 60 Mineral Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 min acupuncture treatment
Trial: 18050628
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (all groups)
Trial: 15929963
Drug: Predicted R(L)
RxNorm normalized name: L-methionine-S,R-sulfoximine
DrugBank: Methionine sulfoximine (DB14103)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predicted R(L) from X(rs)
Trial: 12593524
Drug: Beclometasone dipropionate
RxNorm normalized name: Beclometasone dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beclometasone dipropionate (BDP) suspension for nebulization 3,000-4,000 microg/day b.i.d. via nebulizer
Trial: 12593524
Drug: Beclometasone dipropionate
RxNorm normalized name: Beclometasone dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beclometasone dipropionate (BDP) spray 1,500-2,000 microg/day b.i.d. via metered-dose inhaler (MDI) plus spacer
Trial: 8712434
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl 1 microgram/kg
Trial: 1986567
Drug: EPO (2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPO (2,000 U IV three times a week) + nandrolone decanoate (100 mg IM weekly)
Trial: 30428891
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU) - typical daily clinical practice
Trial: 11748952
Drug: Micronised purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronised purified flavonoid fraction (MPFF) 500 mg twice daily for 60 days
Trial: 11748952
Drug: Placebo 500
RxNorm normalized name: placebo 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 500 mg twice daily for 60 days
Trial: 9709879
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B colloidal dispersion (ABCD) 4 mg/(kg.d)
Trial: 9709879
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B 0.8 mg/(kg.d)
Trial: 7654480
Drug: Microemulsion formulation
RxNorm normalized name: cyclosporine microemulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microemulsion formulation of cyclosporin (Neoral), 10 mg kg‐1
Trial: 7654480
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral formulation of cyclosporin (Sandimmun), 10 mg kg‐1
Trial: 7654480
Drug: Microemulsion formulation
RxNorm normalized name: cyclosporine microemulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microemulsion formulation of cyclosporin (Neoral)
Trial: 364615
Drug: Ketoprofen (50+50+100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (50+50+100 mg)
Trial: 364615
Drug: Naproxen (250+250+250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (250+250+250 mg)
Trial: 31850976
Drug: Compression stockings
RxNorm normalized name: Truform Medical Compression Stockings
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression stockings for 7 days (with concurrent phlebectomies)
Trial: 29654563
Drug: Triple antibiotic
RxNorm normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple antibiotic paste (TAP) with minocycline
Trial: 29654563
Drug: TAP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP with amoxicillin
Trial: 21810649
Drug: Divalproex sodium
RxNorm normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex sodium (valproate) at a target dose of 10 to 12 mg per kilogram of body weight per day for 24 months
Trial: 19265311
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg combined with dexamethasone 10 mg
Trial: 17040215
Drug: Caffeine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (200 mg single dose) taken 12 hours prior to melatonin intake
Trial: 17040215
Drug: Caffeine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (200 mg single dose) taken 24 hours prior to melatonin intake
Trial: 17040215
Drug: Melatonin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (6 mg orally)
Trial: 17040215
Drug: Melatonin as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin as a probe drug
Trial: 9161648
Drug: Topical antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antimicrobial gel containing cetrimide, bacitracin, and polymyxin B sulfate
Trial: 9161648
Drug: Povidone iodine
RxNorm normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone iodine antiseptic cream
Trial: 7967362
Drug: Torasemide alone
RxNorm normalized name: torasemide
DrugBank: Torasemide (DB00214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide alone (50 mg i.v.)
Trial: 7967362
Drug: Torasemide +
RxNorm normalized name: torasemide
DrugBank: Torasemide (DB00214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide + Butizid (20 mg i.v.)
Trial: 3307643
Drug: 200 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micrograms of desmopressin tablet
Trial: 3307643
Drug: Desmopressin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin (both oral and nasal)
Trial: 30098126
Drug: Inulin-propionate ester
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inulin-propionate ester (IPE) 20 g/d for 42 days
Trial: 25271185
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg i.m. ketamine
Trial: 25271185
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg i.m. morphine
Trial: 23710492
Drug: Natamycin (5%)
RxNorm normalized name: Natamycin
DrugBank: Natamycin (DB00826)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Natamycin (5%) applied topically every hour while awake until reepithelialization, then 4 times daily for at least 3 weeks
Trial: 23710492
Drug: Voriconazole (1%)
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole (1%) applied topically every hour while awake until reepithelialization, then 4 times daily for at least 3 weeks
Trial: 8431570
Drug: Methylprednisolone sodium
RxNorm normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone sodium succinate (MPSS) 1 g/patient
Trial: 3298752
Drug: Captopril (CAP)
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril (CAP) 37.5 mg/day
Trial: 3298752
Drug: Carteolol (CAR)
DrugBank: Carteolol (DB00521)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carteolol (CAR) 15 mg/day
Trial: 29807307
Drug: Combo stent
RxNorm normalized name: NexGard Combo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combo stent (dual-therapy CD34 antibody-covered sirolimus-eluting stent)
Trial: 22676921
Drug: Prophylactic administration
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic administration of oxytocin 10 IU via Uniject™ by Community Health Officers within one minute of delivery
Trial: 20028969
Drug: Low-insulin high-glucose
RxNorm normalized name: calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal Low Calcium 1.5]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-insulin high-glucose (LIHG; variable insulin, BG of 7-9 mmol/l)
Trial: 20028969
Drug: High-insulin high-glucose
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-insulin high-glucose (HIHG; insulin 2.0 mU.kg(‐1).min(‐1) plus insulin requirement from study 1, BG of 7-9 mmol/l)
Trial: 20028969
Drug: High-insulin low-glucose
RxNorm normalized name: calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal Low Calcium 1.5]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-insulin low-glucose (HILG; insulin 2.0 mU.kg(‐1).min(‐1) plus insulin requirement from study 1, BG of 4-6 mmol/l)
Trial: 9714962
Drug: Mandibular overdenture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular overdenture on permucosal dental implants
Trial: 9714962
Drug: Overdenture on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overdenture on a transmandibular implant
Trial: 7848789
Drug: Doxazosin (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (mean final daily dose 2.9 mg)
Trial: 30293128
Drug: Functional behavior-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional behavior-based cognitive behavior therapy (Fb-CBT)
Trial: 26525623
Drug: Generic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic medication (memantal)
Trial: 22968256
Drug: Low-dose ALN
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ALN (70 mg every two weeks)
Trial: 22968256
Drug: Standard-dose ALN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose ALN (70 mg weekly)
Trial: 18237377
Drug: Postal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postal administration
Trial: 12610178
Drug: Irinotecan weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan weekly (125 mg/m²)
Trial: 12610178
Drug: Irinotecan once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan once every 3 weeks (350 mg/m² or 300 mg/m² for specific patients)
Trial: 9059214
Drug: rocuronium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rocuronium 0.1 mg kg‐1 (group R1)
Trial: 9059214
Drug: rocuronium 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rocuronium 0.3 mg kg‐1 (group R3)